Nanovibronix (FEED) Stock Price, News & Analysis

Company Overview

NanoVibronix, Inc. is a medical device company focused on developing and commercializing noninvasive therapeutic devices that use low-intensity surface acoustic wave technology. Its products are designed to support pain management, wound care and other clinical applications.

The company’s product portfolio has included PainShield, a wearable therapeutic ultrasound device intended to provide localized pain relief, and WoundShield, a device designed to support wound-care treatment. NanoVibronix has also developed UroShield, which is intended for the management of urinary discomfort and related conditions.

NanoVibronix has served healthcare providers and patients in the United States and international markets through medical distribution and sales channels. The company is associated with operations in the United States and Israel. The ticker provided, FEED, does not appear to correspond to NanoVibronix; the company has historically been identified by the Nasdaq symbol NAOV.

Key Stats

• Today's Range: $0.27 to $0.40
• 50-Day Range: $0.38 to $5.57
• 52-Week Range: $0.27 to $89.40
• Volume: 3,603 shs
• Average Volume: 400,476 shs
• Market Capitalization: $246.71 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Nanovibronix Stock Analysis - MarketRank™

Nanovibronix scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Nanovibronix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nanovibronix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nanovibronix is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nanovibronix is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nanovibronix has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.99% of the float of Nanovibronix has been sold short.

Short Interest Ratio / Days to Cover

Nanovibronix has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanovibronix has recently decreased by 81.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanovibronix does not currently pay a dividend.

Dividend Growth

Nanovibronix does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.95

News Sentiment

Nanovibronix has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Nanovibronix this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for FEED on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

3 people have added Nanovibronix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanovibronix insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of Nanovibronix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

16.39% of the stock of Nanovibronix is held by institutions.

Company Calendar

• Last Earnings: 8/17/2026
• Today: 9/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:FEED
• CIK: 1326706
• Web: nanovibronix.com
• Phone: (914) 233-3004
• Fax: 914-376-6111
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($117.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.18 million
• Net Margins: -1,093.61%
• Pretax Margin: -1,111.94%
• Return on Equity: -60.73%
• Return on Assets: -48.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.66
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $1.93 million
• Price / Sales: 0.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $365.43 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 924,000
• Free Float: 810,000
• Market Cap: $246.71 thousand
• Optionable: N/A
• Beta: 1.38